SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

8 Oct 2015 07:00

RNS Number : 5861B
Victrex PLC
08 October 2015
 



 

 

 

 

 

 

8 October 2015

 

Victrex plc - Full year pre-close trading update

 

"A good finish to 2015"

 

Victrex plc, an innovative world leader in high performance polymer solutions, today announces its full year pre-close trading update for the financial year ended 30 September 2015, ahead of its preliminary results on 8 December 2015.

 

Victrex delivered a good finish to 2015, with overall performance in line with our expectations, including a robust fourth quarter (Q4). For the year as a whole, the value of our balanced portfolio helped to drive growth and fully overcome headwinds including weaker sales in Oil & Gas, the effects of US Spine market consolidation on our Invibio medical business and the significant impact from foreign currency this year.

 

On a reported basis, full year Group revenue of £263.5m was 4% ahead of the prior year (FY 2014: £252.6m), with Q4 Group revenue of £68.7m being flat on the prior year period. Foreign currency, at a profit level, was a headwind of approximately £8m for the full year, which we will fully overcome.

 

At a volume level, full year Group sales volume of 4,217 tonnes was 19% ahead of the prior year (FY 2014: 3,551 tonnes). Q4 Group sales volume of 1,119 tonnes was 6% ahead of the prior year period (Q4 2014: 1,056 tonnes). Sales volumes reflect our overall momentum in VPS remaining positive during the fourth quarter, with growth across Aerospace, Automotive, General Industrial and strong Consumer Electronics volumes offsetting Oil & Gas, as previously communicated.

 

Invibio performance was in line with our previous guidance, with full year revenue of £50.5m being 5% down compared to the prior year (FY 2014: £53.4m). This reflects the effects of consolidation in the US Spine market.

 

Outlook

Our overall growth momentum remains positive as we start our new financial year. Whilst we are mindful of the continuing weakness in Oil & Gas and the need to improve Invibio performance in 2016, our balanced portfolio keeps us well placed to continue driving growth and creating value, in line with our long term strategy.

 

Enquiries:

 

Victrex plc:

Andrew Hanson, Head of Investor Relations & Communications +44 (0) 1253 898121

Louisa Burdett, Group Finance Director +44 (0) 1253 897700

David Hummel, Chief Executive +44 (0) 1253 897700

 

Pendomer Communications:

Charles Armitstead +44 (0) 203 603 5220

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions focused on the Aerospace, Automotive, Electronics, Energy and Medical markets. Every day, millions of people rely on products or applications which contain our polymers, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years' experience, we are delivering leading edge solutions to shape future performance for our customers and our markets, and to drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUGGQWUUPAGAM
Date   Source Headline
1st Dec 201712:51 pmRNSBlock listing Interim Review
30th Nov 20171:41 pmRNSTotal Voting Rights
27th Nov 201711:20 amRNSAdditional Listing
17th Nov 20173:57 pmRNSDirector/PDMR Shareholding
31st Oct 20179:41 amRNSTotal Voting Rights
17th Oct 20173:29 pmRNSDirector/PDMR Shareholding
29th Sep 201710:31 amRNSTotal Voting Rights
19th Sep 20172:59 pmRNSDirector/PDMR Shareholding
4th Sep 20177:01 amRNSCEO-designate update
4th Sep 20177:00 amRNSReduction in effective tax rate
31st Aug 20173:31 pmRNSTotal Voting Rights
17th Aug 201711:39 amRNSDirector/PDMR Shareholding
31st Jul 201710:36 amRNSTotal Voting Rights
25th Jul 20177:00 amRNSTrading Statement
18th Jul 20172:10 pmRNSDirector/PDMR Shareholding
30th Jun 20172:09 pmRNSTotal Voting Rights
19th Jun 20174:18 pmRNSDirector/PDMR Shareholding
1st Jun 20179:51 amRNSBlock listing Interim Review
31st May 20179:22 amRNSTotal Voting Rights
31st May 20179:05 amRNSHolding(s) in Company
19th May 20179:39 amRNSAdditional Listing
18th May 201710:23 amRNSDirector/PDMR Shareholding
15th May 20177:00 amRNSHalf-year Report
28th Apr 20172:39 pmRNSTotal Voting Rights
19th Apr 20172:17 pmRNSDirector/PDMR Shareholding
19th Apr 20177:57 amRNSDirectorate Change
6th Apr 20177:00 amRNSAcquisition
31st Mar 201710:32 amRNSTotal Voting Rights
28th Mar 20177:00 amRNSCapital Markets Day
24th Mar 20172:44 pmRNSHolding(s) in Company
17th Mar 20172:12 pmRNSDirector/PDMR Shareholding
17th Mar 20179:34 amRNSHolding(s) in Company
14th Mar 201710:56 amRNSHolding(s) in Company
9th Mar 20174:33 pmRNSHolding(s) in Company
28th Feb 201710:49 amRNSTotal Voting Rights
17th Feb 201711:30 amRNSDirector/PDMR Shareholding
8th Feb 20171:59 pmRNSResult of AGM
8th Feb 20179:00 amRNSAudit Tender Notification
8th Feb 20177:00 amRNSAGM Statement
31st Jan 20173:54 pmRNSTotal Voting Rights
17th Jan 20172:52 pmRNSDirector/PDMR Shareholding
5th Jan 201711:31 amRNSAnnual Financial Report
30th Dec 201611:37 amRNSHolding(s) in Company
30th Dec 201610:00 amRNSTotal Voting Rights
21st Dec 20169:14 amRNSDirector Declaration
19th Dec 201612:54 pmRNSDirector/PDMR Shareholding
15th Dec 20169:02 amRNSDirector Declaration
8th Dec 20163:41 pmRNSDirector/PDMR Shareholding
6th Dec 20167:00 amRNSFinal Results
1st Dec 201611:53 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.